Trial Profile

Pacritinib in Combination With Azacitidine in Patients With Chronic Myelomonocytic Leukemia

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Pacritinib (Primary)
Indications Chronic myelomonocytic leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

17 Jun 2024 Planned initiation date changed from 2 Jan 2024 to 1 Sep 2024.
17 Jun 2024 Status changed from not yet recruiting to recruiting.
12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com